ArticleJACC. Advances2026
Metabolomic Atlas of Cardiovascular Diseases: Mapping Shared and Specific Signatures.
Article in JACC. Advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCardiovascular disease (CVD) remains the leading global cause of death. While metabolic dysregulation is central to CVD pathogenesis, the extent to which distinct clinical subtypes exhibit unique or shared metabolic signatures remains unclear.
objectivesThe purpose of this study was to systematically characterize metabolomic patterns across a broad spectrum of CVD subtypes and to delineate both shared and subtype-specific metabolic features.
methodsWe analyzed nuclear magnetic resonance-based metabolomic data (325 metabolites) from 244,567 UK Biobank participants, including 27,950 with prevalent CVDs classified into 87 phenotypes (37 classes, 50 subclasses) using International Classification of Diseases-10th Revision codes. Logistic regression, random forest, and XGBoost models assessed cross-sectional metabolite-disease associations. SHapley Additive exPlanations analysis identified key discriminative features. Internal geographic validation used Scotland and Wales cohorts.
resultsMetabolomic profiles demonstrated substantial heterogeneity across CVD subtypes. We identified 21 metabolites consistently associated with multiple conditions, including Intermediate-Density Lipoprotein cholesteryl esters, linoleic acid percentage, and small very low_density lipoprotein particles, reflecting shared alterations in lipoprotein metabolism and inflammatory pathways. Cross-sectional discrimination models achieved moderate-to-high performance for prevalent disease status (eg, chronic ischemic heart disease area under the curve = 0.876). Disease similarity clustering revealed reproducible organizational structures: ischemic entities formed tight clusters, hypertensive-renal diseases showed graded patterns, while rheumatic and pulmonary conditions remained distinct. These patterns were confirmed in geographic validation cohorts.
conclusionsThis comprehensive metabolomic atlas reveals both shared and subtype-specific metabolic alterations across prevalent CVD. The identified metabolite set provides a hypothesis-generating framework for understanding cardiovascular metabolic heterogeneity. However, the cross-sectional design and inclusion of treated patients preclude causal or predictive inference, requiring validation in prospective, treatment-naive cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.